Direxion Daily S&P Biotech Bear 3X ETF
LABD
18 hedge funds and large institutions have $8.35M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
226% more call options, than puts
Call options by funds: $17.8M | Put options by funds: $5.47M
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
50% more funds holding
Funds holding: 12 → 18 (+6)
30.72% less ownership
Funds ownership: 45.05% → 14.33% (-31%)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
76% less capital invested
Capital invested by funds: $35.5M → $8.35M (-$27.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$2.14M |
| 2 |
Jane Street
New York
|
+$1.46M |
| 3 |
HF
HRT Financial
New York
|
+$1.15M |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$471K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$466K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$27.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.63M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.51M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$947K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$211K |
LABD Hedge Fund Activity: Q2 2021 in Review
18 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2021, worth a combined $8.35M — down 76% from $35.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LABD positions and 3 closed out — a net gain of 6 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $2.14M. The largest seller was Boxer Capital, exiting entirely with an estimated $27.2M sold.
- 18 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2021, up from 12 in Q1 2021.
- Funds reported $8.35M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2021, down 76% quarter-over-quarter.
- 9 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2021 and 3 closed out, a net change of +6 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2021 was Virtu Financial, an estimated $2.14M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q2 2021 was Boxer Capital, an estimated $27.2M sold.
Based on aggregated 13F filings for Q2 2021.